Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients
N Iwata, KA Tourian, E Hwang, L Mele… - Journal of Psychiatric …, 2013 - journals.lww.com
Background. This study evaluated the efficacy and safety of low-dose desvenlafaxine
(administered as desvenlafaxine succinate) in treating major depressive disorder (MDD) …
(administered as desvenlafaxine succinate) in treating major depressive disorder (MDD) …
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major …
MR Liebowitz, KA Tourian, E Hwang, L Mele… - BMC psychiatry, 2013 - Springer
Background In an effort to establish the lowest effective dose of desvenlafaxine
(administered as desvenlafaxine succinate), we assessed the efficacy, safety, and …
(administered as desvenlafaxine succinate), we assessed the efficacy, safety, and …
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
MR Liebowitz, AL Manley… - … medical research and …, 2008 - Taylor & Francis
Objective: To assess the efficacy, safety, and tolerability of 50-and 100-mg/day doses of
desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine …
desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine …
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician
S Reddy, C Kane, B Pitrosky, J Musgnung… - … medical research and …, 2010 - Taylor & Francis
Background: Major depressive disorder (MDD) is a common, seriously impairing illness.
Desvenlafaxine (administered as desvenlafaxine succinate) is the third serotonin …
Desvenlafaxine (administered as desvenlafaxine succinate) is the third serotonin …
Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder
SG Kornstein, AH Clayton, CN Soares… - Journal of clinical …, 2010 - journals.lww.com
This pooled analysis evaluated the efficacy of desvenlafaxine (administered as
desvenlafaxine succinate) for the treatment of major depressive disorder (MDD) in patients …
desvenlafaxine succinate) for the treatment of major depressive disorder (MDD) in patients …
An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder
JL Carrasco, SG Kornstein, RS McIntyre… - International Clinical …, 2016 - journals.lww.com
The chronic course of major depressive disorder (MDD) often impedes the ability of patients
to achieve full remission. Return of full functioning is a critical goal of antidepressant …
to achieve full remission. Return of full functioning is a critical goal of antidepressant …
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
MR Liebowitz, PP Yeung, R Entsuah - Journal of Clinical …, 2007 - psychiatrist.com
Objective: This study evaluated the efficacy and tolerability of desvenlafaxine succinate
(desvenlafaxine) in the treatment of major depressive disorder (MDD). Method: In this 8 …
(desvenlafaxine) in the treatment of major depressive disorder (MDD). Method: In this 8 …
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
NA DeMartinis, PP Yeung, R Entsuah… - Journal of Clinical …, 2007 - psychiatrist.com
Objective: This study evaluated the efficacy and safety of desvenlafaxine succinate extended-
release in major depressive disorder (MDD). Method: Adult outpatients with DSM-IV–defined …
release in major depressive disorder (MDD). Method: Adult outpatients with DSM-IV–defined …
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
P Boyer, S Montgomery, U Lepola… - International clinical …, 2008 - journals.lww.com
The objective of this study was to assess the efficacy, safety, and tolerability of
desvenlafaxine (administered as desvenlafaxine succinate) 50 and 100 mg/day for major …
desvenlafaxine (administered as desvenlafaxine succinate) 50 and 100 mg/day for major …
[HTML][HTML] Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials
MR Liebowitz, KA Tourian - The Primary Care Companion for CNS …, 2010 - psychiatrist.com
Objective: Desvenlafaxine is the third serotonin-norepinephrine reuptake inhibitor (SNRI)
approved by the US Food and Drug Administration for major depressive disorder (MDD) …
approved by the US Food and Drug Administration for major depressive disorder (MDD) …